Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2015-16 | Page 37

Beximco Pharmaceuticals Limited
Statement of Cash Flows
For 18 Months Period ended 30th June 2016

Amount in Taka

| Particulars | Note | January 2015 - June 2016 (18 Months) | January - December 2014 (12 Months) |
|---|---|---|---|
| **Cash Flows from Operating Activities:** | | | |
| Receipts from Customers and Others | | 19,756,621,890 | 11,085,037,894 |
| Payments to Suppliers and Employees | | (15,204,763,705) | (8,240,584,352) |
| **Cash Generated from Operations** | | **4,551,858,185** | **2,844,453,542** |
| Interest Paid | | (1,030,182,401) | (724,314,963) |
| Interest Received | | 404,847,333 | 489,970,647 |
| Income Tax Paid | | (757,245,805) | (394,128,824) |
| **Net Cash Generated from Operating Activities** | | **3,169,277,312** | **2,215,980,402** |
| **Cash Flows from Investing Activities:** | | | |
| Acquisition of Property, Plant and Equipment | | (2,975,250,144) | (2,778,797,453) |
| Intangible Assets | | (165,351,713) | (56,321,506) |
| Disposal of Property, Plant and Equipment | | 9,583,953 | 7,615,792 |
| Dividend Received | | 1,427,955 | 1,427,955 |
| Decrease in Short Term Investment | | 1,035,989,018 | 551,356,330 |
| **Net Cash Used in Investing Activities** | | **(2,093,600,931)** | **(2,274,718,882)** |
| **Cash Flows from Financing Activities:** | | | |
| Net Increase/(Decrease) in Long Term Borrowings- Note 18 (c) | | 55,519,429 | (340,756,861) |
| Net Increase/(Decrease) in Short Term Borrowings- Note 18 (c) | | (378,148,721) | 376,855,168 |
| Dividend Paid | | (754,165,099) | (350,853,554) |
| **Net Cash Generated from Financing Activities** | | **(1,076,794,391)** | **(314,755,247)** |
| **Increase/(Decrease) in Cash and Cash Equivalents** | | **(1,118,010)** | **(373,493,727)** |
| Cash and Cash Equivalents at Beginning of Period | | 222,239,239 | 595,732,966 |
| **Cash and Cash Equivalents at End of Period** | | **221,121,229** | **222,239,239** |

| Particulars | Note | January 2015 - June 2016 (18 Months) | January - December 2014 (12 Months) |
|---|---|---|---|
| **Net Operating Cash Flow Per Share** | | **8.21** | **6.02** |
| Number of Shares used to compute Net Operating Cash Flow Per Share | | 386,244,234 | 367,851,652 |

The Notes are an integral part of the Financial Statements.
Approved and authorised for issue by the Board of Directors on 6 October, 2016 and signed for and on behalf of the Board :

Beximco Pharmaceuticals Limited
Notes to the Financial Statements
As at and for the period ended 30 June 2016

### 1. Reporting entity

### 1.1 About the company
Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL took over Beximco Infusions Ltd., a listed company of the Beximco Group engaged in manufacturing and marketing of intravenous fluids and got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka.

### 1.2 Nature of Business
The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products including life saving intravenous fluids, Therapeutic Nutrition Products and Active Pharmaceutical Ingredients (APIs). Products of the company are sold in domestic and international markets. The company also provides contract manufacturing services.

### 2. Basis of Preparation of Financial Statements

### 2.1 Basis of Measurement
The financial statements have been prepared on Historical Cost Basis except land, building and plant & machinery being revalued on 31 December 2008, investment in shares of listed company being valued at year end quoted price and the cash flow statement being prepared on cash basis.

### 2.2 Statement of Compliance
The financial statements have been prepared in compliance with the requirements of the Companies Act, 1994, the Securities & Exchange Rules 1987, the Listing Regulations of Dhaka and Chittagong Stock Exchanges and other relevant local laws as applicable and in accordance with the International Financial Reporting Standards (IFRSs), and Bangladesh Financial Reporting Standards (BFRSs).

### 2.3 Presentation of Financial Statements
The presentation of the financial statements is in accordance with the guidelines provided by IAS 1: Presentation of Financial Statements.

The financial statements comprises of:
(a) a Statement of Financial Position as at the end of the period ended 30 June 2016 ;
(b) a Statement of Profit or Loss and Other Comprehensive Income for the period 01 January 2015 to 30 June 2016 (18 months);
(c) a Statement of Changes in Equity for the period 01 January 2015 to 30 June 2016 (18 months);
(d) a Statement of Cash Flows for the period 01 January 2015 to 30 June 2016 (18 months); and
(e) notes, comprising summary of significant accounting policies and explanatory information.

### 2.4 Reporting Period & Comparative Information
The financial statements have been prepared for 18 (eighteen) months (from $1^{\text{st}}$ January 2015 to $30^{\text{th}}$ June 2016) as per directive of Bangladesh Securities and Exchange Commission (BSEC) to facilitate the adoption of reporting period of July to June in place of existing reporting period of calendar year (January to December) in compliance to the requirement of the National Board of Revenue (NBR) to follow uniform financial year.

Therefore, the financial statements for the period of 18 months (01.01.2015 to 30.06.2016) are not entirely comparable with the comparative of 12 months (01.01.2014 to 31.12.2014).